Loading
Tweaking the antibody's tail to make it recruit immune cells more strongly, or not at all.
Fc engineering means tweaking the antibody's tail, the Fc region, so that it recruits immune cells more strongly, or not at all. Afucosylation and Fc mutations enhance ADCC, whereas Fc-silencing through an IgG4 backbone or LALA mutations prevents unwanted immune activation in checkpoint inhibitors and T-cell engagers, and FcRn-binding mutations extend half-life. The term is linked to the Monoclonal antibodies and Bispecific antibodies technologies and to the terms Antibody, NK cell and Half-life. It is cited by the drug records for Margetuximab, Tislelizumab and Mogamulizumab, by the pathways on myeloid suppression, complement in cancer and NK-cell recognition, and by an idea on bispecific antibodies that engage macrophages instead of T cells.
Showing the technology this term belongs to: Monoclonal antibodies.
Shares NK cell, Margetuximab, Mogamulizumab, Antibody.
Shares Complement in cancer, NK-cell recognition: missing self & stress ligands.
Shares Complement in cancer, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.
Shares Antibody, Monoclonal antibodies.
Shares Antibody, Monoclonal antibodies.
Shares Bispecific antibodies that engage macrophages instead of T cells, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Monoclonal antibodies.
Shares Mogamulizumab, Monoclonal antibodies.
Shares Mogamulizumab, Monoclonal antibodies.